The total return over the past 12 months is -19.33% vs. +16.94% for the S&P 500. So far it's up -1.26% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (19.33%) | +112.06% | +28.09% | +1.87% | N/A | N/A |
| Total Return CAGR | (19.33%) | +112.06% | +28.09% | +1.87% | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Summit Therapeutics Inc. (SMMT)
| Year | Start price | End price | SMMT Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $17.49 | $17.27 | (1.26%) | +14.51% | (15.77%) |
| 2025 | $17.85 | $17.49 | (2.02%) | +17.72% | (19.74%) |
| 2024 | $2.61 | $17.85 | +583.91% | +24.89% | +559.02% |
| 2023 | $4.25 | $2.61 | (38.59%) | +26.19% | (64.78%) |
| 2022 | $2.69 | $4.25 | +57.99% | (18.17%) | +76.16% |
| 2021 | $4.70 | $2.69 | (42.77%) | +28.74% | (71.51%) |
| 2020 | $1.60 | $4.70 | +193.75% | +18.37% | +175.38% |
| 2019 | $1.15 | $1.60 | +39.13% | +31.22% | +7.91% |
| 2018 | $11.08 | $1.15 | (89.62%) | (4.56%) | (85.06%) |
| 2017 | $8.56 | $11.08 | +29.44% | +21.70% | +7.74% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
